With GreenGene F, GC Pharma became third in the world to successfully develop a third-generation recombinant protein drug for hemophilia-A. As such, the product epitomizes the company’s technological innovation and expertise. Having been approved for Phase 3 clinical trials, the drug is currently under drug approval process in China, a market with a huge potential for growth. By continuing to research and develop next-generation long acting hemophilia treatments, GC Pharma will expand its presence in the North American and European markets as well and increase its share of the global market.
GC Pharma remains committed to improving the products that have already won government and market approval, continuing to improve quality and diversifying dosages and types. IVIG-SN, human normal immunoglobulin for immunodeficiency, has obtained approval in 15 countries worldwide and is enjoying growing demand in South America and elsewhere. Currently under Phase 3 clinical trial in the United States, the product is expected to be launched on the American market in a few years.
GC Pharma succeeded in developing Neulapeg, a treatment for neutropenia, in 2014. Designed as a supplement for immunosuppressant chemotherapy and thereby minimizing the treatment’s side effects, Neulapeg offers a longer half-life than its first-generation product. It has also enabled the Korean medical community to cease importing similar drugs from overseas. In addition, GC Pharma is working on introducing an innovative antibody production technology. The company continues to research and develop new candidate materials for immunotherapy for cancer patients. Its specialized subsidiaries are also helping the company strengthen its position in cell therapy, which is emerging as a new potential source of economic growth.
At GC Pharma, we believe it our duty to research and develop treatments for rare diseases, which are difficult to make and enjoy little market prospect, but which are crucial to saving lives. The first success in this regard came in the form of Hunterase, a treatment for Hunter syndrome, a hereditary metabolic disorder also known as mucopolysaccharidosis (MPS) type-II, in 2012. As the second Hunter syndrome treatment to be developed in the world, Hunterase has helped to lighten the financial burden on Korean patients and families by replacing the expensive imported alternative, and significantly improved quality of life for patients. Under GC Pharma’s plan to bring this innovative drug to Hunter syndrome patients around the world, it has been introduced into eight South American and North African markets. Recently NDA was submitted in China, and it is currently under clinical trials in many countries as well.
GC Pharma has been accumulating expertise in plasma derivatives, vaccines, and recombinant proteins. In the process, the company has made significant impact on treatment for patients and on public health. GC Pharma is now ready to maximize and upgrade the values of its existing products, and engage in strategic R&D activities to further strengthen its pipeline of products against a wider range of diseases.